Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
Medical College of Wisconsin
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company
Eli Lilly and Company